These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
328 related articles for article (PubMed ID: 27382574)
1. Increasing GLP-1 Circulating Levels by Bariatric Surgery or by GLP-1 Receptor Agonists Therapy: Why Are the Clinical Consequences so Different? Amouyal C; Andreelli F J Diabetes Res; 2016; 2016():5908656. PubMed ID: 27382574 [TBL] [Abstract][Full Text] [Related]
2. Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges. Huang X; Liu J; Peng G; Lu M; Zhou Z; Jiang N; Yan Z J Endocrinol; 2024 Sep; 262(3):. PubMed ID: 38916409 [TBL] [Abstract][Full Text] [Related]
3. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'. Skow MA; Bergmann NC; Knop FK Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961 [TBL] [Abstract][Full Text] [Related]
4. Effects of gastric inhibitory polypeptide, glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists on Bone Cell Metabolism. Hansen MSS; Tencerova M; Frølich J; Kassem M; Frost M Basic Clin Pharmacol Toxicol; 2018 Jan; 122(1):25-37. PubMed ID: 28722834 [TBL] [Abstract][Full Text] [Related]
5. Incretin hormones: Their role in health and disease. Nauck MA; Meier JJ Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():5-21. PubMed ID: 29364588 [TBL] [Abstract][Full Text] [Related]
6. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Nauck MA; Meier JJ Lancet Diabetes Endocrinol; 2016 Jun; 4(6):525-36. PubMed ID: 26876794 [TBL] [Abstract][Full Text] [Related]
7. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity. Iepsen EW; Torekov SS; Holst JJ Expert Opin Pharmacother; 2014 Dec; 15(17):2487-500. PubMed ID: 25260877 [TBL] [Abstract][Full Text] [Related]
8. The entero-insular axis: implications for human metabolism. Ranganath LR Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966 [TBL] [Abstract][Full Text] [Related]
9. Incretins and Their Endocrine and Metabolic Functions. Seufert J Endocr Dev; 2017; 32():38-48. PubMed ID: 28873383 [TBL] [Abstract][Full Text] [Related]
10. Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans. Dupre J Regul Pept; 2005 Jun; 128(2):149-57. PubMed ID: 15780434 [TBL] [Abstract][Full Text] [Related]
11. Roux-en-Y gastric bypass versus calorie restriction: support for surgery per se as the direct contributor to altered responses of insulin and incretins to a mixed meal. Berggren J; Lindqvist A; Hedenbro J; Groop L; Wierup N Surg Obes Relat Dis; 2017 Feb; 13(2):234-242. PubMed ID: 27894746 [TBL] [Abstract][Full Text] [Related]
12. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice. Hansotia T; Drucker DJ Regul Pept; 2005 Jun; 128(2):125-34. PubMed ID: 15780432 [TBL] [Abstract][Full Text] [Related]
13. [Modulation of the incretin effect in the treatment of diabetes]. Vidal J Med Clin (Barc); 2014; 143 Suppl 2():8-11. PubMed ID: 25326837 [TBL] [Abstract][Full Text] [Related]
14. Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus : Focus on Bile Acid Sequestrants. Holst JJ; McGill MA Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 27933595 [TBL] [Abstract][Full Text] [Related]
15. Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes. Capozzi ME; DiMarchi RD; Tschöp MH; Finan B; Campbell JE Endocr Rev; 2018 Oct; 39(5):719-738. PubMed ID: 29905825 [TBL] [Abstract][Full Text] [Related]
16. How to fight obesity with antidiabetic drugs: targeting gut or kidney? Baretić M; Troskot R Minerva Endocrinol; 2015 Mar; 40(1):71-83. PubMed ID: 25366984 [TBL] [Abstract][Full Text] [Related]
17. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Laferrère B; Heshka S; Wang K; Khan Y; McGinty J; Teixeira J; Hart AB; Olivan B Diabetes Care; 2007 Jul; 30(7):1709-16. PubMed ID: 17416796 [TBL] [Abstract][Full Text] [Related]
18. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus]. Escalada FJ Med Clin (Barc); 2014; 143 Suppl 2():2-7. PubMed ID: 25326836 [TBL] [Abstract][Full Text] [Related]
19. Canagliflozin potentiates GLP-1 secretion and lowers the peak of GIP secretion in rats fed a high-fat high-sucrose diet. Hira T; Koga T; Sasaki K; Hara H Biochem Biophys Res Commun; 2017 Oct; 492(2):161-165. PubMed ID: 28803984 [TBL] [Abstract][Full Text] [Related]
20. Obesity management for the treatment of type 2 diabetes: emerging evidence and therapeutic approaches. Morissette A; Mulvihill EE J Pharm Pharm Sci; 2024; 27():13065. PubMed ID: 38903652 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]